Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY22 results · Jan–Mar 2022
Ajanta Pharma reported revenue from operations of ₹870.29 crore (up 15.0% from Q4 FY21) and net profit of ₹151.21 crore (down 5.1% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 870.29 | 756.84 | +15.0% | 837.91 | +3.9% |
| Other income | 29.48 | 2.53 | 12x | 24.03 | +22.7% |
| Total income | 899.77 | 759.37 | +18.5% | 861.94 | +4.4% |
| Profit before tax | 197.67 | 228.78 | −13.6% | 230.94 | −14.4% |
| Net profit for the period | 151.21 | 159.26 | −5.1% | 191.78 | −21.2% |
| EPS, basic (₹) | 17.70 | 18.40 | −3.8% | 22.16 | −20.1% |
| Net margin (%) | 17.4 | 21.0 | 22.9 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 765.63 | 748.07 | +2.3% | 808.58 | −5.3% |
| Other income | 28.42 | 1.33 | 21x | 27.90 | +1.9% |
| Total income | 794.05 | 749.40 | +6.0% | 836.48 | −5.1% |
| Profit before tax | 178.30 | 216.75 | −17.7% | 234.36 | −23.9% |
| Net profit for the period | 134.84 | 154.78 | −12.9% | 194.71 | −30.7% |
| EPS, basic (₹) | 15.79 | 17.89 | −11.7% | 22.50 | −29.8% |
| Net margin (%) | 17.6 | 20.7 | 24.1 |
Consolidated
- Filed with BSE
- 11 May 2022, 12:34 IST
- Board meeting
- 10 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 May 2022, 12:34 IST
- Board meeting
- 10 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE